IDEXX Laboratories (NASDAQ:IDXX) Releases Quarterly Earnings Results, Beats Estimates By $0.25 EPS

IDEXX Laboratories (NASDAQ:IDXX) announced its quarterly earnings data on Monday. The company reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.71 by $0.25, FiscalAI reports. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the business posted $3.22 earnings per share.

Here are the key takeaways from IDEXX Laboratories’ conference call:

• IDEXX raised its 2026 outlook, increasing revenue guidance to $4.741 billion–$4.767 billion and EPS guidance to $14.96–$15.16. The company now expects 9.3%–10% organic revenue growth and 15%–16% comparable EPS growth.
• Third-quarter performance was strong, with 10% organic revenue growth, 11% organic growth in companion-animal diagnostics recurring revenue, and 22% comparable EPS growth. Growth was volume-led and supported by international expansion, new customers, premium instrument placements, and increased diagnostic utilization.
• Innovation momentum remains a major growth driver. IDEXX placed 5,780 premium instruments, including 1,904 inVue Dx analyzers, while expanding inVue Dx FNA availability, the Cancer Dx panel, Catalyst proBNP, and software capabilities.
• The company said inVue Dx placements are on track to exceed its 2026 target of 5,500 and its five-year goal of 20,000, with strong international demand and additional upside from FNA and future menu expansion.
• U.S. same-store clinical visits declined an estimated 1.8%, with muted puppy and kitten adoption trends and ongoing macroeconomic pressure. The CoVet acquisition is expected to dilute 2026 operating margin by approximately 30 basis points and EPS by about $0.13 per share in the near term, although management expects margin expansion as integration progresses.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded up $26.67 during trading hours on Wednesday, reaching $698.71. The company’s stock had a trading volume of 307,122 shares, compared to its average volume of 576,378. The firm has a market capitalization of $55.04 billion, a price-to-earnings ratio of 47.16 and a beta of 1.55. IDEXX Laboratories has a 1-year low of $500.61 and a 1-year high of $769.98. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 0.87. The company’s 50-day moving average is $538.81 and its two-hundred day moving average is $573.69.

Key Stories Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Third-quarter EPS of $3.96 and revenue of $1.21 billion topped analyst estimates; revenue grew 9.9% year over year. IDEXX also raised its 2026 EPS outlook to $14.96–$15.16, above the cited consensus estimate, and forecast revenue of $4.7–$4.8 billion. The results and outlook helped drive a substantial recent stock advance. IDXX Q3 Earnings & Revenues Surpass Estimates
• Positive Sentiment: Morgan Stanley maintained an Overweight rating and raised its price target to $810, signaling continued analyst confidence in the company’s execution and growth prospects. Morgan Stanley stock recommendations
• Neutral Sentiment: Analysts noted that diagnostics growth is helping offset a lackluster veterinary-visit backdrop. That resilience supports results, but trends in clinic visits remain an important business factor. IDEXX raises forecast, betting diagnostics can offset weak vet visits
• Negative Sentiment: A fresh Seeking Alpha rating downgrade argues that IDEXX is a strong company but its shares are too expensive. Valuation concerns could weigh on the stock, particularly following its recent rally. IDEXX Laboratories: Great Company, But Too Expensive

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a research report on Tuesday. UBS Group upped their price objective on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the company a “neutral” rating in a report on Tuesday. KeyCorp assumed coverage on shares of IDEXX Laboratories in a research note on Monday, October 12th. They issued a “sector weight” rating on the stock. Barclays reduced their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. decreased their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research report on Friday, October 16th. Seven research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $719.55.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.